{
  "id": "61f5f580882a024a10000017",
  "type": "summary",
  "question": "What is the mechanism of action of Lanifibranor?",
  "ideal_answer": "Lanifibranor is peroxisome proliferator-activated receptor (PPAR) agonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32613381",
    "http://www.ncbi.nlm.nih.gov/pubmed/29446942",
    "http://www.ncbi.nlm.nih.gov/pubmed/33038502",
    "http://www.ncbi.nlm.nih.gov/pubmed/32360434",
    "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
    "http://www.ncbi.nlm.nih.gov/pubmed/33278455",
    "http://www.ncbi.nlm.nih.gov/pubmed/34670042",
    "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
    "http://www.ncbi.nlm.nih.gov/pubmed/34488870"
  ],
  "snippets": [
    {
      "text": "These cell systems were then used to evaluate the anti-NASH properties of eight peroxisome proliferator-activated receptor (PPAR) agonists (bezafibrate, elafibranor, fenofibrate, lanifibranor, pemafibrate, pioglitazone, rosiglitazone, and saroglitazar).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32613381",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34488870",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We have examined peroxisome proliferator-activated receptor (PPAR) pathway perturbation in this model and explored the impact of the pan-PPAR agonist lanifibranor on the cardiorespiratory phenotype.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34488870",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33278455",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Given the current lack of an effective treatment, we aimed to characterise the effects of the pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor in 2 preclinical models of ACLD, as well as in liver cells from patients with ACLD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33278455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This explains the manifold metabolic pathways as antifibrotic targets, including farnesoid X receptor (FXR) agonism (obeticholic acid, nonsteroidal FXR agonists), acetyl-CoA carboxylase inhibition, peroxisome proliferator-activator receptor agonism (elafibranor, lanifibranor, saroglitazar), and fibroblast growth factor (FGF)-21 or FGF-19 activation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30261763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While several promising drug candidates failed in phase 2 or 3 clinical trials (including elafibranor, emricasan and selonsertib), promising results with the farnesoid X receptor agonist obeticholic acid, the pan-PPAR agonist lanifibranor and the chemokine receptor CCR2/CCR5 inhibitor cenicriviroc support the expectation of an effective pharmacological therapy for liver fibrosis in the near future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33987427",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Starting with a PPAR\u03b1 activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29446942",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lanifibranor (IVA337), a panPPAR agonist, by acting on these three different PPAR isotypes, combines pharmacological effects that could address the different components of the disease as demonstrated in preclinical models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33038502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34670042",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34670042",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "cal need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis o",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34670042",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo onc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34670042",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "a metabolically activated phenotype. Lanifibranor attenuated the accompanying inflammatory activation in both murine palmitic acid-stimulated bone marrow-derived macrophages, as well as patient-derived circulating monocytes, in a PPAR\u03b4-dependent fashion.CONCLUSION: Pan-PPAR agonists combine the beneficial effects of selective PPAR agonists and may counteract in",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32360434",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lammation and disease progression more potently. PPAR\u03b4 agonism and lanifibranor directly modulate macrophage activation, but not infiltration, thereby synergizing with beneficial metabolic effects of PPAR\u03b1/\u03b3 agonists.LAY SUMMARY: Peroxisome proliferated-activated receptors (P",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32360434",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}